Industry Strength Score
66/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NRX PHARMACEUTICALS INC (NRXP) Stock Price & Overview
NASDAQ:NRXP • US6294442099
Current stock price
2.89 USD
-0.02 (-0.69%)
Last:
The current stock price of NRXP is 2.89 USD. Today NRXP is down by -0.69%. In the past month the price increased by 36.62%. In the past year, price increased by 41.67%.
NRXP Key Statistics
52-Week Range1.62 - 3.84
Current NRXP stock price positioned within its 52-week range.
1-Month Range2.11 - 3.29
Current NRXP stock price positioned within its 1-month range.
- Market Cap
- 95.572M
- P/E
- N/A
- Fwd P/E
- 9.44
- EPS (TTM)
- -1.03
- Dividend Yield
- N/A
NRXP Stock Performance
Today
-0.69%
1 Week
-2.02%
1 Month
+36.62%
3 Months
+38.57%
Longer-term
6 Months -6.13%
1 Year +41.67%
2 Years +12.79%
3 Years -49.93%
5 Years N/A
10 Years N/A
NRXP Stock Chart
NRXP Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NRXP. When comparing the yearly performance of all stocks, NRXP is one of the better performing stocks in the market, outperforming 88.27% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NRXP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NRXP. Both the profitability and financial health of NRXP have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NRXP Earnings
On March 23, 2026 NRXP reported an EPS of -0.01 and a revenue of 983.00K. The company missed EPS expectations (-370.59% surprise) and missed revenue expectations (-87.19% surprise).
Next Earnings DateMay 13, 2026
Last Earnings DateMar 23, 2026
PeriodQ4 / 2025
EPS Reported-$0.01
Revenue Reported983K
EPS Surprise -370.59%
Revenue Surprise -87.19%
NRXP Forecast & Estimates
10 analysts have analysed NRXP and the average price target is 38.76 USD. This implies a price increase of 1241.18% is expected in the next year compared to the current price of 2.89.
For the next year, analysts expect an EPS growth of 129.65% and a revenue growth 169.49% for NRXP
Analysts
Analysts84
Price Target38.76 (1241.18%)
EPS Next Y129.65%
Revenue Next Year169.49%
NRXP Index Membership
NRXP is currently included in the following stock indexes tracked on ChartMill.
NRXP Financial Highlights
Over the last trailing twelve months NRXP reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS increased by 55.32% compared to the year before.
Income Statements
Revenue(TTM)1.23M
Net Income(TTM)-28.62M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -220.92% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%98.44%
Sales Q2Q%N/A
EPS 1Y (TTM)55.32%
Revenue 1Y (TTM)N/A
NRXP Ownership
Ownership
Inst Owners25.16%
Shares33.07M
Float30.32M
Ins Owners5.39%
Short Float %10.72%
Short Ratio3.66
NRXP Industry Overview
NRXP operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
35%
Outperformed 35% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
37%
Outperformed 37% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 3.7%
- New Lows
- 4.4%
- Average ROE
- 50.6%
- Average Profit Margin
- 27.8%
- Average Operating Margin
- 37.5%
- Average P/E
- 25.0
- Average Fwd P/E
- 19.7
- Average Debt/Equity
- 1.2
NRXP Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.42 | 804.24B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 547.597B | ||
| MRK | MERCK & CO. INC. | 21.82 | 274.033B | ||
| PFE | PFIZER INC | 8.95 | 149.376B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.42 | 117.584B | ||
| ZTS | ZOETIS INC | 16.18 | 47.868B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.72 | 28.553B | ||
| VTRS | VIATRIS INC | 6.03 | 17.431B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 20.91 | 10.887B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.409B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.108B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.796B | ||
| CORT | CORCEPT THERAPEUTICS INC | 86.52 | 4.956B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NRXP
Company Profile
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
Company Info
IPO: 2017-11-20
NRX PHARMACEUTICALS INC
1201 Orange Street, Suite 600
Wilmington DELAWARE US
CEO: Richard Ackerman
Employees: 29
Phone: 14842546134
NRX PHARMACEUTICALS INC / NRXP FAQ
What does NRX PHARMACEUTICALS INC do?
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
What is the stock price of NRX PHARMACEUTICALS INC today?
The current stock price of NRXP is 2.89 USD. The price decreased by -0.69% in the last trading session.
Does NRX PHARMACEUTICALS INC pay dividends?
NRXP does not pay a dividend.
What is the ChartMill rating of NRX PHARMACEUTICALS INC stock?
NRXP has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does NRX PHARMACEUTICALS INC belong to?
NRX PHARMACEUTICALS INC (NRXP) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the PE ratio for NRXP stock?
NRX PHARMACEUTICALS INC (NRXP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.03).